Dr. Elizabeth O'Day is the CEO and Founder of Olaris, Inc., a precision medicine company that uses a pioneering metabolomics platform and proprietary machine learning algorithms to fundamentally improve how disease is diagnosed and treated. Olaris identifies “biomarkers of response” (BoR) to stratify patients into optimal treatment groups, increasing survival rates, decreasing adverse events, and reducing unnecessary healthcare costs. Dr. O’Day serves on the Personalized Medicine Coalition (PMC) Board of Directors. In this role, Dr. O’Day collaborates with stakeholders across academia, industry, and government to increase access to personalized medicine. Dr. O’Day also supports the next generation of scientists as adjunct faculty at Boston College, where she taught metabolism and entrepreneurship. Dr. O’Day was recognized by Boston Business Journal as a 40 under 40 honoree in 2020. She is also on the Steering Committee and a contributor for Scientific American's annual "Top 10 Emerging Technologies". During her graduate and undergraduate studies, Dr. O’Day received many of the most prestigious research awards for her personal scientific accomplishments. She earned her Ph.D. from Harvard University, where she was a National Science Fellow; an MPhil in Chemistry from the University of Cambridge where she was a Churchill Fellow; and a BS in Biochemistry from Boston College where she was a Finnegan Award winner, Beckman Scholar, and Goldwater Scholar.